We make this in a patent-pending base that helps absorb the larger semaglutide molecule As of April 22, 2025, the compounded injectable semaglutide will no longer be available due to the FDAs declaration of drug shortages being removed
10.3389/fpsyt.2025.1656969 Front
The glucagon-driven thermogenesis ramps up without causing excessive metabolic stress
39(4): 5929 Debska-Slizien A, Kawecka A, Wojnarowski K, et al
Patients should contact their healthcare provider promptly if they experience: Severe, persistent abdominal pain that worsens or differs from typical bloating Inability to pass gas or have bowel movements (possible obstruction) Persistent vomiting that prevents adequate hydration or medication adherence Unintentional weight loss beyond expected therapeutic effects Blood in stool or black, tarry stools Fever accompanying gastrointestinal symptoms Right upper quadrant pain or yellowing of skin/eyes (possible gallbladder disease) Severe constipation with abdominal distension (possible ileus/obstruction) Signs of dehydration (excessive thirst, dark urine, dizziness) These symptoms may indicate complications such as pancreatitis, gallbladder disease, bowel obstruction, or acute kidney injuryall noted in FDA prescribing information as potential risks
